



Distinguished Professor, Director, Graduate Institute of Biomedical Sciences,  
College of Medicine

Director, Department of Psychiatry, College of Medicine

Ph.D., National Defense Medical Center (Taiwan), 2000

M.D., Taipei Medical University (Taiwan), 1987

Phone: (886)-4-22052121 ext 1855, 1074

Email: [hylane@gmail.com](mailto:hylane@gmail.com)

URL: [http://gibs.cmu.edu.tw/english/faculty\\_clinical.html](http://gibs.cmu.edu.tw/english/faculty_clinical.html)

**Research Interests:** Neuropsychopharmacology, Cognitive neuroscience, Precision medicine

#### Academic Distinctions:

Y.Z. Hsu Scientific Paper Award, Biotechnology Category, Taiwan (2006)

The 10th & 14th National Innovation Award, Taiwan (2013, 2017)

The 24th Wang-Ming-Ning Award, Taiwan (2014)

Ministry of Science and Technology Outstanding Research Award, Taiwan (2014)

CNS Drug Innovation Award, The International of College of Neuropsychopharmacology (2016)

#### Appointments:

2006-2008: Adjunct Research Fellow, Institute of Biomedical Sciences, Academia Sinica

2009-present: Distinguished Professor, Director, Graduate Institute of Clinical Medical Science,  
CMU

2015-present: Director, Brain Disease Research Center, CMU and Hospital

2016-present: Distinguished Professor, Director, Graduate Institute of Biomedical Sciences, CMU

#### Research Interests:

Dr. Hsien-Yuan Lane's research interests primarily focus on neuropsychopharmacology. In recent years, his study aims to (1) determine genetic and non-genetic determinants for treatment response of mental disorders; (2) develop novel NMDA-enhancing agents for treating mental disorders and dementia. These studies are innovative, carefully designed and likely to revolutionize our understanding and care of patients afflicted with mental disorders or dementia.

#### Representative Publications:

[Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.](#) Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. *Arch Gen Psychiatry.* 2005 Nov;62(11):1196-204.

[Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.](#) Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY\*, Tsai GE. *Biol Psychiatry.* 2013 Nov 15;74(10):734-41.

[Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.](#) Lane HY, Lin CH, Green MF, Helleman G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE. *JAMA Psychiatry.* 2013 Dec;70(12):1267-75.

[Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.](#) Lin CH, Chen PK, Chou LJ, Chang YC, Chen YS, Tsai GE, Lane HY\*. *Biol Psychiatry.* 2014 May; 75(9):678-85.

[Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals.](#) Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai, G, Lane HY\*. *Mol Psychiatry.* 2014 June 19(6):636-7.

[Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.](#) Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Yang HT, Lane HY\*. *Biol Psychiatry.* 2017 Dec 26. pii: S0006-3223(17)32297-7. doi: 10.1016/j.biopsych.2017.12.006. [Epub ahead of print]